Evidence map›Paper›PMID 34312410›Full record

ArticleScientific reports2021

Knockout of Ca

Irem Kilicarslan, Lucia Zanetti, Elena Novelli, Christoph Schwarzer, Enrica Strettoi, Alexandra Koschak

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Irem Kilicarslan *Institute of Pharmacy, Pharmacology and Toxicology, Center for Chemistry and Biomedicine, University of Innsbruck, Innrain 80-82, 6020, Innsbruck, Austria.
Lucia Zanetti *Institute of Pharmacy, Pharmacology and Toxicology, Center for Chemistry and Biomedicine, University of Innsbruck, Innrain 80-82, 6020, Innsbruck, Austria.
Elena NovelliCNR Neuroscience Institute, 56124, Pisa, Italy.
Christoph SchwarzerDepartment of Pharmacology, Medical University of Innsbruck, 6020, Innsbruck, Austria.
Enrica StrettoiCNR Neuroscience Institute, 56124, Pisa, Italy. enrica.strettoi@in.cnr.it.
Alexandra KoschakInstitute of Pharmacy, Pharmacology and Toxicology, Center for Chemistry and Biomedicine, University of Innsbruck, Innrain 80-82, 6020, Innsbruck, Austria. alexandra.koschak@uibk.ac.at.
Universität Innsbruck · ATNeuroscience Institute · ITInnsbruck Medical University · AT

Funding

Austrian Science Fund FWF P 29359
6 · The paper itself

Abstract

Retinitis Pigmentosa is a genetically heterogeneous, degenerative retinal disorder characterized by gradual dysfunction and death of photoreceptors, first rods and later cones, and progressive blindness. Studies suggested that application of L-type calcium channel blockers rescues photoreceptors in paradigms related to Ca

Indexed as

AnimalsCalcium Channels, L-TypeCyclic Nucleotide Phosphodiesterases, Type 6Disease Models, AnimalImmunohistochemistryMiceMice, Inbred C57BLMice, KnockoutMice, Mutant StrainsRetinal Cone Photoreceptor CellsRetinal Rod Photoreceptor CellsRetinitis PigmentosaCacna1d protein, mouseCalcium Channels, L-TypeCyclic Nucleotide Phosphodiesterases, Type 6Pde6b protein, mouse

Identifiers

PMID34312410
PMCPMC8313562
OpenAlexW3185517495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.